<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lactic acid, citric acid, and potassium bitartrate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lactic acid, citric acid, and potassium bitartrate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lactic acid, citric acid, and potassium bitartrate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="128326" href="/d/html/128326.html" rel="external">see "Lactic acid, citric acid, and potassium bitartrate: Drug information"</a> and <a class="drug drug_patient" data-topicid="128348" href="/d/html/128348.html" rel="external">see "Lactic acid, citric acid, and potassium bitartrate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54453271"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Phexxi</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F54441773"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Contraceptive</span></li></ul></div>
<div class="block dop drugH1Div" id="F54441778"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d8874c8-e0f3-47c9-a18f-f794ce8d5154">Contraception</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception:</b> Postmenarche patients: Intravaginal: 1 prefilled applicator (5 g) immediately before or up to 1 hour before each act of vaginal intercourse; repeat dose if vaginal intercourse does not occur within 1 hour of administration; an additional dose is needed if &gt;1 act of vaginal intercourse occurs within 1 hour. <b>Note:</b> Not effective for the prevention of pregnancy when administered after vaginal intercourse.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F54441779"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F54441781"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F54483868"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="128326" href="/d/html/128326.html" rel="external">see "Lactic acid, citric acid, and potassium bitartrate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d8874c8-e0f3-47c9-a18f-f794ce8d5154">Contraception</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception:</b>
<b>Intravaginal:</b> Insert the contents of 1 prefilled applicator vaginally immediately before or up to 1 hour before each act of vaginal intercourse. An additional dose is needed if vaginal intercourse does not occur within 1 hour of insertion. One application is needed for each act of vaginal intercourse; if more than 1 act of vaginal intercourse occurs within 1 hour, additional doses must be applied.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F54483870"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely (not systemically absorbed).</p></div>
<div class="block doha drugH1Div" id="F54483871"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely (not systemically absorbed).</p></div>
<div class="block adr drugH1Div" id="F54453896"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Genitourinary: Vulvovaginal burning (18%), vulvovaginal pruritus (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bacterial vaginosis (8%), dysuria (3%), urinary tract infection (9%), vaginal discharge (6%), vaginal discomfort (9%), vaginal pain (2%), vulvar pain (genital discomfort: 4%), vulvovaginal candidiasis (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Local discomfort (male partners: 10%; burning, itching, pain [mild: 75%, moderate: 20%, severe: 4%])</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Pyelonephritis</p></div>
<div class="block coi drugH1Div" id="F54431332"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F54483862"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Genitourinary effects: Avoid use in patients with a history of recurrent urinary tract infections (UTIs) or urinary tract abnormalities. Cystitis, upper UTIs, and pyelonephritis (requiring hospitalization in one case) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vulvovaginal effects: Burning and pruritus may occur; effects are usually mild but may require discontinuation in some cases.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• HIV infection protection: Use of this product does not protect against HIV infection or other sexually transmitted diseases.</p></div>
<div class="block foc drugH1Div" id="F54453272"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Vaginal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phexxi: Lactic acid 1.8%, citric acid 1%, and potassium bitartrate 0.4% (5 g) [contains benzoic acid]</p></div>
<div class="block geq drugH1Div" id="F54453270"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54494495"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Phexxi Vaginal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.8-1-0.4% (per gram): $6.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F54441804"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Vaginal: Use within 1 hour prior to vaginal intercourse. Wash hands before using. Remove pink cap prior to use. Hold the prefilled applicator at the grooved area and gently insert prefilled applicator of gel into vagina; press the plunger to release the medication. Discard used prefilled applicators and pink cap after use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Administer an additional dose if vaginal intercourse does not occur within 1 hour of administration.</p></div>
<div class="block adm drugH1Div" id="F54483872"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intravaginal:</b> For vaginal administration only. May be used at any time during the menstrual cycle. May be used following childbirth, abortion, or miscarriage once vaginal intercourse is safe to resume. Avoid use with vaginal rings. May be used concomitantly with hormonal contraceptives, condoms (latex, polyurethane, and polyisoprene), and vaginal diaphragms. May be used concomitantly with intravaginal products for vaginal infections (including miconazole, metronidazole, or tioconazole).</p></div>
<div class="block sts drugH1Div" id="F54483864"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store in original foil pack at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F54441777"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention of pregnancy as an on-demand method of contraception (FDA approved in postmenarche patients).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not effective for the prevention of pregnancy when administered after vaginal intercourse.</p></div>
<div class="block cyt drugH1Div" id="F54443115"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54443112"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ethinyl Estradiol: May diminish the therapeutic effect of Lactic Acid, Citric Acid, and Potassium Bitartrate.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54483860"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">This product is a nonhormonal contraceptive, intended to prevent pregnancy when used immediately prior to or up to 1 hour prior to vaginal intercourse. It may be used at any time during the menstrual cycle, and after childbirth, abortion, or miscarriage once it is safe to resume vaginal intercourse. It is not effective for contraception <i>after</i> vaginal intercourse.</p>
<p style="text-indent:0em;margin-top:2em;">Avoid use with vaginal rings. May be used concomitantly with hormonal contraceptives, condoms (latex, polyurethane, and polyisoprene), and vaginal diaphragms.</p>
<p style="text-indent:0em;margin-top:2em;">In a premarketing study, the cumulative pregnancy rate was 13.7% (95% CI: 10% to 17.5%) over 7 cycles of typical use.</p>
<p style="text-indent:0em;margin-top:2em;">Male partners may experience local discomfort (eg, burning, itching, pain); symptoms are most commonly mild to moderate in severity.</p>
<p style="text-indent:0em;margin-top:2em;">In general, all available forms of contraception can be considered for patients on gender-affirming testosterone therapy after evaluating patient preferences and medical conditions (Bonnington 2020; Krempasky 2020).</p></div>
<div class="block pri drugH1Div" id="F54483859"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">This product is intended to prevent pregnancy; it should not be used if pregnancy has been confirmed.</p></div>
<div class="block mopp drugH1Div" id="F54441805"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of hypersensitivity.</p></div>
<div class="block pha drugH1Div" id="F54483865"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Following vaginal application, the combination of lactic acid, citric acid, and potassium bitartrate maintains vaginal pH in an acidic range and decreases sperm motility. In addition to providing rapidly reversible contraception, this product has also been evaluated for lubricant and antimicrobial properties (Nelson 2018).</p></div>
<div class="block phk drugH1Div" id="F54483866"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Not systemically absorbed (Nelson 2018).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216192"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Phexxi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32304766">
<a name="32304766"></a>Bonnington A, Dianat S, Kerns J, et al. Society of Family Planning clinical recommendations: contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. <i>Contraception</i>. 2020;102(2):70-82. doi:10.1016/j.contraception.2020.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lactic-acid-citric-acid-and-potassium-bitartrate-pediatric-drug-information/abstract-text/32304766/pubmed" id="32304766" target="_blank">32304766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31394072">
<a name="31394072"></a>Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. <i>Am J Obstet Gynecol.</i> 2020;222(2):134-143. doi:10.1016/j.ajog.2019.07.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lactic-acid-citric-acid-and-potassium-bitartrate-pediatric-drug-information/abstract-text/31394072/pubmed" id="31394072" target="_blank">31394072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30136907">
<a name="30136907"></a>Nelson AL. An overview of properties of Amphora (acidform) contraceptive vaginal gel. <i>Expert Opin Drug Saf</i>. 2018;17(9):935-943. doi:10.1080/14740338.2018.1515197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lactic-acid-citric-acid-and-potassium-bitartrate-pediatric-drug-information/abstract-text/30136907/pubmed" id="30136907" target="_blank">30136907</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Phexxi (lactic acid, citric acid, and potassium bitartrate) [prescribing information]. San Diego, CA: Evofem Inc; February 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 128377 Version 35.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
